Ayala Pharmaceuticals (NASDAQ:ADXS) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a research report report published on Friday. The brokerage issued a sell rating on the stock.

Ayala Pharmaceuticals Stock Performance

Shares of Ayala Pharmaceuticals stock opened at $0.03 on Friday. Ayala Pharmaceuticals has a 1 year low of $0.00 and a 1 year high of $1.49. The company has a market cap of $1.15 million, a P/E ratio of 0.00 and a beta of 1.70. The stock has a 50-day moving average price of $0.04 and a 200 day moving average price of $0.08.

Ayala Pharmaceuticals Company Profile

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.